Overview
BBNX market data
Price History
BBNX price chart · 1M
- O
- 17.35
- H
- 17.43
- L
- 16.34
- C
- 16.35
- Vol
- 37,069.00
Daily history from Jan 30, 2025
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $17.35
- Previous Close
- $17.34
- Day High
- $17.43
- Day Low
- $16.34
- 52 Week High
- $32.53
- 52 Week Low
- $8.81
- 7 Day Return
- -7.31%
- 30 Day Return
- -26.42%
- 90 Day Return
- -8.25%
- 1 Year Return
- -20.90%
- Daily Notional Volume
- $606.1K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.81 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.78 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -61.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $8.80 – $32.71 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $910.1M · P/B 4.66 · P/S 7.65.
Company News
10 captured
Jefferies Initiates Coverage On Beta Bionics with Buy Rating, Announces Price Target of $30Benzinga ·
BBNX Stockholders Have Rights – If You Lost Money Investing in Beta Bionics, Inc. Contact Robbins LLP for Information About Recovering Your LossesGlobenewswire Inc ·
Wells Fargo Initiates Coverage On Beta Bionics with Overweight Rating, Announces Price Target of $28Benzinga ·
Kaplan Fox Alerts Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to a Pending Securities Class Action – Deadline is November 3, 2026Globenewswire Inc ·
8-K filing — Beta Bionics, Inc. (BBNX)SEC EDGAR ·